Jamie Bell
Abbott announces “first-in-world” leadless pacing procedures in left bundle branch area...
Abbott has announced the successful completion of the “world's first” in-human leadless left bundle branch area pacing (LBBAP) procedures using the company's investigational Aveir...
HeartBeam announces US FDA clearance for at-home, high-fidelity heart monitoring technology
HeartBeam has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance of the HeartBeam system for comprehensive arrhythmia assessment. A...
US FDA issues alert over potential need for early device replacement...
The US Food and Drug Administration (FDA) has alerted patients, caregivers and healthcare providers about the potential need for early device replacement of Boston...
FieldForce ablation system earns US FDA TAP pilot acceptance and breakthrough...
Field Medical has announced that its FieldForce ablation system has been accepted into the US Food and Drug Administration (FDA)’s Total Product Life Cycle Advisory...
CathVision unveils EMR integration and new report generator in ECGenius system...
CathVision has unveiled the latest ECGenius system update—a release that brings essential enhancements to streamline workflows and boost procedural efficiency in electrophysiology (EP) labs,...
BTL Medical announces successful first-in-human treatments with novel PFA catheter
BTL Medical has announced the successful treatment of the first six patients in a first-in-human feasibility study using its next-generation catheter system designed to...
Manipal Hospitals successfully performs eastern India’s first AI-powered wireless pacemaker insertion
Manipal Hospitals—one of the largest healthcare networks in India—has announced the successful insertion of an artificial intelligence (AI)-driven wireless injectable pacemaker.
The Aveir leadless...
Pilot study shows cryoablation safe and effective for patent foramen ovale...
New research suggests that cryoablation is a safe and effective approach to closing congenital patent foramen ovale (PFO) in patients with atrial fibrillation (AF)...
Texas Cardiac Arrhythmia Institute becomes first in USA to use FDA-approved...
Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St David's Medical Center (Austin, USA) recently became the first in the USA to use...
AHA 2024: Three trials shed new light on AF ablation outcomes
Late-breaking results from the PROMPT-AF, CRRF-PeAF and ARREST-AF trials were presented recently at the American Heart Association (AHA) Scientific Sessions (16–18 November 2024, Chicago, USA),...
Accurate prediction of sudden cardiac death following heart attack “currently not...
New research published in the European Heart Journal has shown that, among patients who have had a heart attack, it is “extremely difficult” to accurately predict...
AHA 2024: Lifestyle and risk-factor changes improve AF symptoms—not burden—compared to...
Treatment with the Type 2 diabetes medication metformin, lifestyle changes, or a combination of both, did not improve atrial fibrillation (AF) burden or progression...
COVID-19 vaccination “generally not associated” with increased thromboembolic event risk in...
In patients with atrial fibrillation (AF) or atrial flutter, COVID-19 vaccination appears to be “generally not associated with an increased risk of thromboembolic events”,...
AHA 2024: Blood thinners fail to reduce cognitive decline in younger...
Prescribing anticoagulation medications to adults younger than 65 years of age who have atrial fibrillation (AF) but no other risk factors for stroke does not...
AHA 2024: Ablation potentially superior to medication for post-heart attack VT
Ablation may be a better first-line treatment for heart attack survivors experiencing dangerous episodes of ventricular tachycardia (VT), according to late-breaking science presented recently...
AHA 2024: Reconditioned pacemakers appear to perform as well as new...
A randomised trial comparing previously used and new pacemakers in patients with heart rhythm disorders has found reconditioned devices to be as safe and...
Two innovative ECG monitors obtain new US FDA clearances
Two innovative electrocardiogram (ECG) products have gained new US Food and Drug Administration (FDA) clearances for monitoring cardiac arrhythmias—Fourth Frontier’s Frontier X Plus (FX+)...
Defibrillation devices could remain effective while using 1,000 times less electricity
In a paper published recently in the journal Chaos, researchers from Sergio Arboleda University (Bogotá, Colombia) and the Georgia Institute of Technology (Atlanta, USA) used...
Study indicates more exercise is better—but even moderate amounts may reduce...
An extra hour of physical activity every week may lower a person’s chance of developing the most common type of arrythmia by 11%, a...
University of Kansas Health System enhances robotic heart care programme with...
Stereotaxis has announced that physicians at the University of Kansas Health System (Kansas City, USA)—a system renowned for diagnosing and treating complex heart conditions—have...
Collaboration attempts to establish research capacity for ambulatory rhythm monitoring in...
A recent study published in JACC: Clinical Electrophysiology has placed emphasis on the importance of building research capacity for ambulatory rhythm monitoring in sub-Saharan...
Pulse appoints David Kenigsberg as Electrophysiology CMO and adds Andrea Natale...
Pulse Biosciences has announced the appointment of David Kenigsberg (Florida Heart Rhythm Specialists, Fort Lauderdale, USA) as chief medical officer (CMO) of Electrophysiology. In...
J&J MedTech receives US FDA approval for Varipulse PFA platform in...
Johnson & Johnson (J&J) MedTech has announced the US Food and Drug Administration (FDA) approval of the Varipulse pulsed field ablation (PFA) platform for...
“Transformative” new data advocate early blood-thinning therapy in patients with atrial...
People with atrial fibrillation (AF) who have a stroke could benefit from receiving blood-thinning treatments—known as direct oral anticoagulants (DOACs)—at an earlier stage than...
MedLumics treats first 10 patients in AblaView clinical study and announces...
MedLumics recently announced that 10 patients have been treated in the company’s first-in-man clinical trial, which is ongoing and currently under protocol-dictated follow-up. The...
Boston Scientific announces agreement to acquire Cortex
Boston Scientific Corporation announced today that it has entered into a definitive agreement to acquire Cortex, an Ajax Health company and privately held medical...
Adagio completes first procedures in pivotal study of VT cryoablation system
Adagio Medical has announced the completion of the first procedures in the FULCRUM-VT US Food and Drug Administration (FDA) pivotal investigational device exemption (IDE)...
Abbott initiates TEAM-HF trial to improve outcomes in advanced heart failure...
Abbott has announced a new, “first-of-its-kind” clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy...
HRS establishes new advocacy organisation to address needs of electrophysiologists and...
The Heart Rhythm Society (HRS) board of trustees has unanimously approved the formation of Heart Rhythm Advocates—a new, shared-vision, cause-related non-profit 501(c)(4) advocacy organisation...
Boston Scientific launches next generation of cardiac mapping for Farapulse PFA...
Boston Scientific Corporation has announced that it has received US Food and Drug Administration (FDA) approval of the navigation-enabled Farawave Nav ablation catheter for...
Abbott progresses PFA clinical studies, launches new advanced cardiac mapping technology
Abbott announced today that it has achieved new, major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology.
These...
Adjunctive coronary sinus isolation confers no additional benefits over PVI ablation...
Adjunctive coronary sinus isolation (CSI) as part of a de-novo ablation strategy does not confer any additional benefit compared to pulmonary vein isolation (PVI)...
AF pattern at first diagnosis does not appear to influence post-ablation...
A patient’s pattern of atrial fibrillation (AF) at their initial diagnosis does not influence their rate of AF recurrence, nor their AF burden, following...
HRS releases new policy statement underscoring requirements for AF catheter ablation
The Health Policy and Regulatory Affairs Committee of the Heart Rhythm Society (HRS) has published a statement online in the Heart Rhythm Journal reaffirming the important role...
Boston Scientific receives Japanese regulatory approval for Farapulse PFA system
Boston Scientific has announced receipt of Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the Farapulse pulsed field ablation (PFA) system. The...
New clinical data show “excellent lesion durability” with Medtronic’s PulseSelect PFA...
Medtronic has announced the presentation of clinical study results demonstrating a high rate of durable lesion formation with the PulseSelect pulsed field ablation (PFA)...
Boston’s Empower leadless pacemaker demonstrates “excellent overall clinical performance” in MODULAR...
Boston Scientific recently announced late-breaking data from the MODULAR ATP clinical trial investigating the pacing performance of the company’s Empower leadless pacemaker. The data...
Cerenovus and Biosense Webster among brands newly incorporated into Johnson &...
Johnson & Johnson (J&J) recently shared that its medical technology businesses—including Cerenovus and Biosense Webster, as well as Abiomed, DePuy Synthes, and Ethicon—will now...
Merit Medical signs agreement to purchase lead management portfolio from Cook...
Merit Medical Systems has announced that it recently signed a definitive asset purchase agreement to purchase Cook Medical’s lead management portfolio for a total...
PULSE-EU: single-shot spherical array PFA catheter achieves good clinical efficacy at...
The treatment of atrial fibrillation (AF) via a novel, ‘single-shot’ spherical array approach to pulsed field ablation (PFA) has been found to achieve durable...
Final results from Medtronic’s EV ICD pivotal trial demonstrate high ATP...
Medtronic recently shared long-term results from the global EV ICD pivotal trial, reinforcing the performance and safety of the company’s extravascular implantable cardioverter defibrillator...
Quitting smoking reduces risk of atrial fibrillation, new study shows
Quitting cigarettes can significantly lower a person’s risk of atrial fibrillation (AF) compared to those who continue to smoke, according to a study published...
Boston Scientific appoints Angelo Auricchio as chief medical officer for EMEA...
Boston Scientific has announced the appointment of Angelo Auricchio as chief medical officer (CMO) of the company’s Rhythm Management business in Europe, the Middle...
ESC 2024: Mass AF screening via ECG plus heart failure biomarker...
Mass screening for atrial fibrillation (AF) using electrocardiography (ECG) together with a heart failure biomarker does not prevent ischaemic stroke or systemic in older...
Abbott brings “world’s first” dual-chamber leadless pacemaker to the UK
Abbott has announced that, as of 6 September, it will be rolling out its Aveir dual-chamber (DR) leadless pacemaker system across the UK. In...
ESC 2024: Widely performed additional ablation procedure deemed ineffective in persistent...
In patients with persistent atrial fibrillation (AF), standard treatment with pulmonary vein isolation (PVI) ablation resulted in similar outcomes to more extensive ablation in...
ESC 2024: Randomised trial shows education for healthcare professionals can improve...
Adherence to atrial fibrillation (AF) guideline recommendations was found to be poor in clinical practice across Europe—but, a structured educational programme for healthcare professionals...
HeartKey Rhythm suite launched following US FDA clearance
B-Secur has announced the US Food and Drug Administration (FDA) clearance and launch of HeartKey Rhythm—a suite of electrocardiogram (ECG) algorithms and analytics designed...
ESC 2024: Wearable monitor increases diagnoses of common heart rhythm disorder...
Screening for atrial fibrillation (AF) using a wearable heart monitor for two weeks can identify older adults with this potentially dangerous abnormal heart rhythm,...
ESC 2024: Simplified AF ablation technique proven advantageous for heart failure...
As per late-breaking research presented recently at the 2024 European Society of Cardiology (ESC) congress (30 August–2 September, London, UK), cryoballoon (CB) ablation is...
ESC 2024: Mainstay ablation procedure for atrial fibrillation shows “substantial benefit”...
A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrial fibrillation (AF), and results...
Job strain and “imbalance between efforts applied versus rewards received” may...
Work-related stress caused by job strain and an “imbalance between efforts applied versus rewards received” may increase the risk of developing atrial fibrillation (AF),...
Danish study results advocate general anaesthesia over conscious sedation in catheter...
A study utilising nationwide healthcare data from across Denmark has indicated that, during catheter ablation procedures, conscious sedation (CS) may be linked to a...
PCORI commits US$57 million to studies evaluating beta-blocking medications and implantable...
The US Patient-Centered Outcomes Research Institute (PCORI) has announced the approval of funding awards totalling more than US$165 million for new patient-centred, comparative clinical...
Pulse Biosciences successfully treats first patients with nano-PFA cardiac surgery system
Pulse Biosciences has announced treatment of the first two patients in a first-in-human feasibility study using its novel nanosecond pulsed field ablation (nsPFA) cardiac...
Adagio and ARYA IV combine to form new company focused on...
Adagio Medical has announced the completion of its business combination with ARYA Sciences Acquisition Corp IV—a special purpose acquisition company sponsored by an affiliate...
Recent US and EU publications underscore potential impact of Jewel defibrillator
Element Science has announced the publication of results from its Jewel investigational device exemption (IDE) study—conducted at sites across the USA—in the Journal of...
Atraverse announces first clinical use of Hotwire RF guidewire system
The Hotwire radiofrequency (RF) guidewire device from Atraverse Medical has been used for the first time in clinical practice by world-renowned cardiac electrophysiologist Devi Nair...
Trial approved for new pacemaker aiming to boost recovery in heart...
Ceryx Medical has announced the approval of a trial evaluating Cysoni-XT—a new temporary cardiac pacemaker aiming to boost recovery in heart failure.
The UK Medicines...
Viz.ai and Medtronic to collaborate on improving post-cryptogenic stroke care in...
Viz.ai has announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between neurology and cardiology teams.
For stroke patients...
Append Medical raises US$4.35 million in initial closing of extended series...
Append Medical has raised US$4.35 million as part of an extended series A round, which will be used to support the company's first-in-human trials of Appligator.
Investors include...
Early anticoagulation after ischaemic stroke “reasonable” and “unlikely to cause harm”
An international clinical trial presented today at the European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany) has demonstrated that—in people with ischaemic stroke...
UK MHRA awarded £10 million to fast-track patient access to medical...
A total of £10 million has been awarded to the Medicines and Healthcare products Regulatory Agency (MHRA)—an executive agency of the UK Department of...
Brainomix technology integrated into new UK atrial fibrillation study
Brainomix has announced its involvement in a new study sponsored by the University of Liverpool (Liverpool, UK) focused on post-stroke atrial fibrillation (AF). Sites...
Continuous monitoring detects atrial fibrillation in 20% of atherosclerotic stroke survivors
In a study presented yesterday at the International Stroke Conference (ISC; 8–10 February, Dallas, USA), irregular heart rhythms were detected in roughly one in...
Atrial fibrillation does not modify treatment effect of bridging thrombolysis, study...
An international study conducted by Leonard Yeo (National University Hospital, Singapore) and colleagues has found that the presence of atrial fibrillation does not modify...
Swiss parliament votes to accept US FDA-approved medical devices
The Swiss Federal Assembly has voted in favour of accepting medical devices with US Food and Drug Administration (FDA) marketing authorisation in Switzerland.
A motion...
Abbott to receive multiple CES 2023 awards for neurostimulation and pacemaker...
Abbott has been recognised by the Consumer Technology Association (CTA) with three Consumer Electronics Show (CES 2023; 5–8 January, Las Vegas, USA) Innovation Awards...
CVRx launches new version of neuromodulation device intended to treat heart...
CVRx—the developer of the “world’s first” US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure—has launched its new...
Medtronic names Laura Mauri as new chief scientific, medical and regulatory...
Medtronic has announced that Laura Mauri has been appointed as the company’s chief scientific, medical and regulatory officer. This appointment adds to Mauri's prior responsibilities...
Remote blood pressure monitoring beneficial for stroke survivors in under-resourced areas
A new strategy using telehealth to monitor blood pressure at home for several months immediately after a stroke had a positive impact on patient engagement and blood...
FDA issues two final guidances for including patient perspectives in medical...
The US Food and Drug Administration (FDA) has issued two final guidances providing recommendations for including patient perspectives in medical device clinical studies.
As...
US physicians “among nation’s first” to implant neurostimulator technology for advanced...
Doctors at St David's Medical Center in Austin, USA recently implanted a new neurostimulator technology in patients to help treat advanced heart failure—and are...
EHRA 2021: Subcutaneous ICDs maintain cardioversion efficacy of 98% across five-year...
Subcutaneous implantable cardioverter defibrillator (S-ICD) devices have demonstrated a cardioversion efficacy rate of 98% over a period of at least five years in the...
EHRA 2021: Efforts should be made to increase participation in atrial...
Further efforts should be made to increase participation in atrial fibrillation (AF) screening—particularly in elderly populations, where systematic screening for AF can help to...